FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

AMGEN Kyprolis Recall

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, Fo…

Amgen, Inc. · Thousand Oaks, CA

Risk level
Class II
Reported by FDA
Dec 28, 2016
Recall ID
D-0226-2017
Check your lot numberHow we source this data

Summary

Amgen recalled AMGEN Kyprolis starting Dec 15, 2016. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0226-2017 on Dec 28, 2016. Reason: Lack of Assurance of Sterility: Potential cracks in glass vials. Status: Terminated.

Why it was recalled

Lack of Assurance of Sterility: Potential cracks in glass vials

Product description

AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01

Lot numbers, UPCs & expiration codes

Lot #1071559, 1071629; Exp. 05/18

Where it was sold

United States and Puerto Rico No foreign distribution.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0226-2017
Classification
Class II
Status
Terminated
Recall initiated
Dec 15, 2016
FDA report date
Dec 28, 2016
Quantity
11,434 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Amgen, Inc.

Original FDA data

Every field from FDA enforcement report D-0226-2017, exactly as published.

Show all FDA fields
City
Thousand Oaks
State
CA
Status
Terminated
Country
United States
Event ID
76012
Address
1 Amgen Center Dr
Code information
Lot #1071559, 1071629; Exp. 05/18
Postal code
91320-1730
Report date
Dec 28, 2016
Product type
Drugs
Recall number
D-0226-2017
Classification
Class II
Recalling firm
Amgen, Inc.
Product quantity
11,434 vials
Termination date
Jun 2, 2017
Reason for recall
Lack of Assurance of Sterility: Potential cracks in glass vials
Voluntary / mandated
Voluntary: Firm initiated
Product description
AMGEN Kyprolis (carfilzomib) for injection, 30 mg per vial, Discard unused portion, For Intravenous Administration Only, Rx Only, Manufactured for: Onyx Pharmaceuticals, Inc., Thousand Oaks, CA 91320-1799, U.S.A., NDC 76075-102-01
Distribution pattern
United States and Puerto Rico No foreign distribution.
Recall initiation date
Dec 15, 2016
Initial firm notification
Letter
Center classification date
Dec 22, 2016

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0226-2017, published Dec 28, 2016. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls